These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29517543)

  • 1. Iodine/FDG "Flip-Flop" Phenomenon Inside a Large Metastatic Thyroid Cancer Lesion Better Characterized on SPECT/CT and PET/CT Studies.
    Duarte PS; Marin JFG; de Carvalho JWA; Sapienza MT; Buchpiguel CA
    Clin Nucl Med; 2018 Jun; 43(6):436-438. PubMed ID: 29517543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of patient age on the iodine/FDG "flip-flop" phenomenon in lung metastasis from thyroid cancer.
    Isoda T; BaBa S; Maruoka Y; Kitamura Y; Tahara K; Sasaki M; Honda H
    Ann Nucl Med; 2016 Oct; 30(8):518-24. PubMed ID: 27380042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interlesional 'flip-flop' between
    Basu S; Kalshetty A; Fargose P
    Natl Med J India; 2017; 30(1):48. PubMed ID: 28731009
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer.
    Terroir M; Borget I; Bidault F; Ricard M; Deschamps F; Hartl D; Tselikas L; Dercle L; Lumbroso J; Baudin E; Berdelou A; Deandreis D; Schlumberger M; Leboulleux S
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):638-646. PubMed ID: 27796544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
    De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
    Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
    Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
    Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer.
    Sakulpisuti C; Charoenphun P; Chamroonrat W
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
    Wu YJ; Wu HS; Yen RF; Shen YY; Kao CH
    Anticancer Res; 2003; 23(3C):2973-6. PubMed ID: 12926147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
    Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
    Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
    Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
    J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Endocrine Neoplasia Type 2B Unmasked by 18 F-FDG PET/CT and 131 I-MIBG SPECT/CT.
    Sun X; Arnous MM; Lan X
    Clin Nucl Med; 2017 Apr; 42(4):297-299. PubMed ID: 28134695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated Metastasis to Spleen-Stomach Space From Follicular Thyroid Cancer Combined With a Benign Subcutaneous Nodule on 18F-FDG PET/CT and 131I Scintigraphy.
    Guo X; He H; Gao Q; Jin Y
    Clin Nucl Med; 2021 Mar; 46(3):e156-e158. PubMed ID: 32910059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.
    Nanni C; Rubello D; Fanti S; Farsad M; Ambrosini V; Rampin L; Banti E; Carpi A; Muzzio P; Franchi R
    Biomed Pharmacother; 2006 Sep; 60(8):409-13. PubMed ID: 16891093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
    Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
    Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
    Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-PET ultrasound improves specificity of 18F-FDG-PET for recurrent differentiated thyroid cancer while maintaining sensitivity.
    Biermann M; Kråkenes J; Brauckhoff K; Haugland HK; Heinecke A; Akslen LA; Varhaug JE; Brauckhoff M
    Acta Radiol; 2015 Nov; 56(11):1350-60. PubMed ID: 25770086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.